Polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) is indicated for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL).
|NCPE Assessment Process||Complete|
|Rapid review commissioned||27/06/2022|
|Rapid review completed||27/07/2022|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pola-R-CHP compared with the current standard of care.|